Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $62 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on PTC Therapeutics (NASDAQ:PTCT) and maintained a $62 price target.
July 16, 2024 | 1:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on PTC Therapeutics and maintained a $62 price target.
The reiteration of an Overweight rating and the maintenance of a $62 price target by a reputable analyst can boost investor confidence in PTC Therapeutics, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100